TuftsCSDD-Logo-Color.jpg
Drug Sponsors and Their External Service Partners Say Adjusting Relationship Models Offers a Path to Greater Performance and Efficiency, According to Tufts Center for the Study of Drug Development
08 oct. 2013 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Oct 8, 2013) - While drug sponsor use of strategic relationships with contract service providers has increased dramatically during the past five years, improvements in...
TuftsCSDD-Logo-Color.jpg
Clinical Study Failures Vary Widely by Phase of Study and Therapeutic Class, According to the Tufts Center for the Study of Drug Development
10 sept. 2013 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Sep 10, 2013) - While lack of commercial viability is the leading cause of Phase I failures for new drug candidates, efficacy issues dominate as the reason for Phase II...
TuftsCSDD-Logo-Color.jpg
Drug Industry Leaders See Collaboration as Key to Greater Productivity, According to Tufts Center for the Study of Drug Development
13 août 2013 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Aug 13, 2013) -  Responding to a widely shared need to improve the probability of R&D success, leaders from the research-based drug industry, recently convened by...
TuftsCSDD-Logo-Color.jpg
Number of Annual New Drug Approvals to Treat Neglected Diseases Has Nearly Doubled Between the Early-2000s and 2009-12, According to the Tufts Center for the Study of Drug Development
11 juil. 2013 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jul 11, 2013) - The annual number of new drug approvals worldwide to treat neglected diseases has nearly doubled in recent years, with HIV/AIDS and malaria drugs...
TuftsCSDD-Logo-Color.jpg
Clinical Success Rates for New Cancer Drugs Doubled From the Mid-1990s to Early-2000s, According to the Tufts Center for the Study of Drug Development
07 mai 2013 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - May 7, 2013) - Clinical success rates for new cancer drugs doubled between the mid-1990s to the early 2000s, while the number of new cancer drugs entering clinical...
TuftsCSDD-Logo-Color.jpg
New Protocol Design Approaches Will Improve Clinical Trial Performance and Efficiency, According to Tufts Center for the Study of Drug Development
09 avr. 2013 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Apr 9, 2013) - Growing protocol complexity -- responsible for longer clinical study times, greater difficulty in recruiting volunteers, and rising drug development costs...
TuftsCSDD-Logo-Color.jpg
Companion Diagnostics, Key to Development of Personalized Medicines, Face Hurdles, According to Tufts Center for the Study of Drug Development
24 janv. 2013 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Jan 24, 2013) - Companion diagnostics, which are central to the creation of personalized medicines, have captured the interest of many drug companies, but face a number of...
TuftsCSDD-Logo-Color.jpg
New Research From Tufts Center for the Study of Drug Development Characterizes Effectiveness and Variability of Patient Recruitment and Retention Practices
15 janv. 2013 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Jan 15, 2013) - While nine out of 10 clinical trials worldwide meet their patient enrollment goals, reaching those targets typically means that drug developers need to...
TuftsCSDD-Logo-Color.jpg
Drug Developers Need to More Fully Identify and Address Root Causes of R&D Inefficiency, According to Tufts Center for the Study of Drug Development
08 janv. 2013 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Jan 8, 2013) - While patent expirations on many top selling medicines are spurring the research-based drug industry to embrace new development paradigms to replenish...
TuftsCSDD-Logo-Color.jpg
Extraneous Data Collected in Clinical Trials Cost Drug Developers $4 Billion to $6 Billion Annually, According to Tufts Center for the Study of Drug Development
06 nov. 2012 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Nov 6, 2012) - One out of every five procedures performed during later stage clinical trials collects extraneous data and costs drug developers more than $1 million per...